No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
LITE240517P45000
- 1.95
- -1.25-39.06%
15min DelayClose May 10 16:00 ET
1.95High1.65Low
1.65Open3.20Pre Close47 Volume318 Open Interest45.00Strike Price8.07KTurnover40.89%IV-0.83%PremiumMay 17, 2024Expiry Date1.21Intrinsic Value100Multiplier5DDays to Expiry0.74Time Value100Contract SizeAmericanOptions Type-0.7007Delta0.1648Gamma27.80Leverage Ratio-0.0702Theta-0.0039Rho-19.48Eff Leverage0.0180Vega
Intraday
- 5D
- 1D
News
TTM Technologies Appoints Lumentum CFO Wajid Ali to Bd of Directors >TTMI
TTM Technologies Appoints Lumentum CFO Wajid Ali to Bd of Directors >TTMI
Research Alert: CFRA Maintains Buy Opinion On Shares Of Lumentum Holdings Inc.
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We trim our 12-month target price by $5
Why Lumentum Holdings Stock Got Trounced on Tuesday
Market players weren't exactly dialed in to telecom equipment specialist Lumentum Holdings (LITE -6.14%) on Tuesday.
Lumentum | 10-Q: Quarterly report
Lumentum Holdings Is Maintained at Underweight by Barclays
Lumentum Holdings Is Maintained at Underweight by Barclays
Lumentum Holdings Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/07/2024 -11.15% Barclays $40 → $38 Maintains Underweight 04/11/2024 33.28% JP Morgan $62 → $57 Maintain
Comments
Matthew Sepe's recent sale suggests he considered a lower price fair, questioning the higher valuation of shares. Despite significant insider ownership indicating alignment, the absence of insider purchases and history of sales call for caution before buying Lumentum Holdings shares.
Have Lumentum Holdings Insiders Been Selling Stock? 1
Despite Lumentum Holdings' recent revenue drop, the market may anticipate a reversal, justifying its high P/S ratio. The company's projected revenue growth, surpassing the Communications industry, could be maintaining share price and shareholder confidence.
The company's balance sheet is strained due to debt and EBIT level loss. Its use of debt is risky, given it burned through US$9.7m of cash last year.
1
Lumentum Holdings is being seen as a valuable investment opportunity due to its future outlook and the fact that it is being undervalued by the stock market. The optimistic growth projections have not yet been fully accounted for in the share price.
Bristol Myers may bolster its treatments portfolio with Karuna acquisition. Ansys' possible undervaluation hinted by takeover speculation. ASML's gear shipment to Intel viewed positively, fostering quicker semiconductor production. Lumentum's upgrade signals bullish prospects for 2024.
3
Read more